Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, PROCEPT BioRobotics Corporation reported revenue of $308M, up 37.2% year over year. Operating margin was -33.7% and net margin -31.0%, on a free-cash-flow margin of -18.9% with capital expenditure at 3.0% of revenue. Every figure is computed directly from PRCT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $308M | -33.7% | -31.0% |
| FY2024 | $224M | -43.0% | -40.7% |
| FY2023 | $136M | -80.2% | -77.8% |
| FY2022 | $75M | -107.6% | -116.2% |
| FY2021 | $34M | -157.1% | -173.6% |
How does PRCT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.